Related Experiment Video
Updated: Nov 10, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
TERT Promoter Alterations in Glioblastoma: A Systematic Review
Nathalie Olympios1, Vianney Gilard2, Florent Marguet3
1Cancer Centre Henri Becquerel, Department of Medical Oncology, Rue d'Amiens, 76000 Rouen, France.
Abstract:
Glioblastoma, the most frequent and aggressive primary malignant tumor, often presents with alterations in the telomerase reverse transcriptase promoter. Telomerase is responsible for the maintenance of telomere length to avoid cell death. Telomere lengthening is required for cancer cell survival and has led to the investigation of telomerase activity as a potential mechanism that enables cancer growth. The aim of this systematic review is to provide an overview of the available data concerning TERT alterations and glioblastoma in terms of incidence, physiopathological understanding, and potential therapeutic implications.

